Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine

Isabella Piassi Godói, Leonardo Vinicius Dias da Silva, Abdur Razzaque Sarker, Itamar Megiddo, Alec Morton, Brian Godman, Samantha Alvarez-Madrazo, Marion Bennie, Augusto Afonso Guerra-Júnior

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Dengue is a serious global health problem endemic in Brazil. Consequently, our aim was to measure the costs and disease burden of symptomatic dengue infections in Brazil from the perspective of the Brazilian Public Health System (SUS) between 2000 and 2015 using Brazilian public health system databases. Specific age group incidence estimates were used to calculate the disability-adjusted life years (DALYs) to gain a better understanding of the disease burden. Areas covered: SUS spent almost USD159 million and USD10 million to treat dengue and severe dengue, respectively, between 2000-2015. This is principally hospitalization costs with the majority of patients self-treated at home with minor symptoms. The average notification rate for dengue was 273 per 100,000 inhabitants and 3 per 100,000 for severe dengue, with annual DALYs estimates ranging between 72.35 to 6,824.45 during the 16 years. Expert commentary: The epidemiological and morbidity burden associated with dengue is substantial in Brazil, with costs affected by the fact that most patients self-treat at home with these costs not included in SUS. The Brazilian government urgently needs to proactively evaluate the real costs and clinical benefits of any potential dengue vaccination program by the National Immunization Program to guide future decision making.

LanguageEnglish
Pages1123–1133
Number of pages11
JournalExpert Review of Vaccines
Volume17
Issue number12
Early online date10 Nov 2018
DOIs
Publication statusE-pub ahead of print - 10 Nov 2018

Fingerprint

Dengue Vaccines
Dengue
Health Policy
Brazil
Public Health
Economics
Severe Dengue
Quality-Adjusted Life Years
Costs and Cost Analysis
Immunization Programs
Cost of Illness
Cost-Benefit Analysis
Decision Making
Vaccination
Hospitalization
Age Groups
Databases
Morbidity
Incidence
Infection

Keywords

  • burden of disease
  • epidemiology
  • economics
  • dengue
  • public health
  • Brazil

Cite this

Godói, Isabella Piassi ; da Silva, Leonardo Vinicius Dias ; Sarker, Abdur Razzaque ; Megiddo, Itamar ; Morton, Alec ; Godman, Brian ; Alvarez-Madrazo, Samantha ; Bennie, Marion ; Guerra-Júnior, Augusto Afonso. / Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine. In: Expert Review of Vaccines. 2018 ; Vol. 17, No. 12. pp. 1123–1133.
@article{9cb74fdd40544b4fb55d17ed982dd140,
title = "Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine",
abstract = "Introduction: Dengue is a serious global health problem endemic in Brazil. Consequently, our aim was to measure the costs and disease burden of symptomatic dengue infections in Brazil from the perspective of the Brazilian Public Health System (SUS) between 2000 and 2015 using Brazilian public health system databases. Specific age group incidence estimates were used to calculate the disability-adjusted life years (DALYs) to gain a better understanding of the disease burden. Areas covered: SUS spent almost USD159 million and USD10 million to treat dengue and severe dengue, respectively, between 2000-2015. This is principally hospitalization costs with the majority of patients self-treated at home with minor symptoms. The average notification rate for dengue was 273 per 100,000 inhabitants and 3 per 100,000 for severe dengue, with annual DALYs estimates ranging between 72.35 to 6,824.45 during the 16 years. Expert commentary: The epidemiological and morbidity burden associated with dengue is substantial in Brazil, with costs affected by the fact that most patients self-treat at home with these costs not included in SUS. The Brazilian government urgently needs to proactively evaluate the real costs and clinical benefits of any potential dengue vaccination program by the National Immunization Program to guide future decision making.",
keywords = "burden of disease, epidemiology, economics, dengue, public health, Brazil",
author = "God{\'o}i, {Isabella Piassi} and {da Silva}, {Leonardo Vinicius Dias} and Sarker, {Abdur Razzaque} and Itamar Megiddo and Alec Morton and Brian Godman and Samantha Alvarez-Madrazo and Marion Bennie and Guerra-J{\'u}nior, {Augusto Afonso}",
year = "2018",
month = "11",
day = "10",
doi = "10.1080/14760584.2018.1546581",
language = "English",
volume = "17",
pages = "1123–1133",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
number = "12",

}

Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine. / Godói, Isabella Piassi; da Silva, Leonardo Vinicius Dias ; Sarker, Abdur Razzaque ; Megiddo, Itamar; Morton, Alec; Godman, Brian; Alvarez-Madrazo, Samantha; Bennie, Marion; Guerra-Júnior, Augusto Afonso.

In: Expert Review of Vaccines, Vol. 17, No. 12, 10.11.2018, p. 1123–1133.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine

AU - Godói, Isabella Piassi

AU - da Silva, Leonardo Vinicius Dias

AU - Sarker, Abdur Razzaque

AU - Megiddo, Itamar

AU - Morton, Alec

AU - Godman, Brian

AU - Alvarez-Madrazo, Samantha

AU - Bennie, Marion

AU - Guerra-Júnior, Augusto Afonso

PY - 2018/11/10

Y1 - 2018/11/10

N2 - Introduction: Dengue is a serious global health problem endemic in Brazil. Consequently, our aim was to measure the costs and disease burden of symptomatic dengue infections in Brazil from the perspective of the Brazilian Public Health System (SUS) between 2000 and 2015 using Brazilian public health system databases. Specific age group incidence estimates were used to calculate the disability-adjusted life years (DALYs) to gain a better understanding of the disease burden. Areas covered: SUS spent almost USD159 million and USD10 million to treat dengue and severe dengue, respectively, between 2000-2015. This is principally hospitalization costs with the majority of patients self-treated at home with minor symptoms. The average notification rate for dengue was 273 per 100,000 inhabitants and 3 per 100,000 for severe dengue, with annual DALYs estimates ranging between 72.35 to 6,824.45 during the 16 years. Expert commentary: The epidemiological and morbidity burden associated with dengue is substantial in Brazil, with costs affected by the fact that most patients self-treat at home with these costs not included in SUS. The Brazilian government urgently needs to proactively evaluate the real costs and clinical benefits of any potential dengue vaccination program by the National Immunization Program to guide future decision making.

AB - Introduction: Dengue is a serious global health problem endemic in Brazil. Consequently, our aim was to measure the costs and disease burden of symptomatic dengue infections in Brazil from the perspective of the Brazilian Public Health System (SUS) between 2000 and 2015 using Brazilian public health system databases. Specific age group incidence estimates were used to calculate the disability-adjusted life years (DALYs) to gain a better understanding of the disease burden. Areas covered: SUS spent almost USD159 million and USD10 million to treat dengue and severe dengue, respectively, between 2000-2015. This is principally hospitalization costs with the majority of patients self-treated at home with minor symptoms. The average notification rate for dengue was 273 per 100,000 inhabitants and 3 per 100,000 for severe dengue, with annual DALYs estimates ranging between 72.35 to 6,824.45 during the 16 years. Expert commentary: The epidemiological and morbidity burden associated with dengue is substantial in Brazil, with costs affected by the fact that most patients self-treat at home with these costs not included in SUS. The Brazilian government urgently needs to proactively evaluate the real costs and clinical benefits of any potential dengue vaccination program by the National Immunization Program to guide future decision making.

KW - burden of disease

KW - epidemiology

KW - economics

KW - dengue

KW - public health

KW - Brazil

UR - https://www.tandfonline.com/loi/ierv20

U2 - 10.1080/14760584.2018.1546581

DO - 10.1080/14760584.2018.1546581

M3 - Article

VL - 17

SP - 1123

EP - 1133

JO - Expert Review of Vaccines

T2 - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 12

ER -